UroGen and MD Anderson to collaborate on bladder cancer treatment
January 14, 2021Cancer, UroGen Pharma
UroGen Pharma, a biopharmaceutical company dedicated to treating specialty cancers and urologic diseases, and The University of Texas MD Anderson …
Celltrion announces positive top-line results from COVID-19 treatment trial
January 14, 2021COVID-19, celltrion
Celltrion Group has announced that top-line results from its global Phase II/III clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody …
Novartis’ ligelizumab granted FDA Breakthrough Therapy Designation
January 14, 2021FDA, Novartis
The FDA has granted Novartis’ ligelizumab Breakthrough Therapy Designation for the treatment of chronic spontaneous urticaria (CSU) in patients who …
COVID-19 vaccine data leaked online by hackers, EMA says
January 14, 2021EMA, Pfizer, Vaccine, data
The EMA has confirmed that data relating to COVID-19 medicines and vaccines that was stolen by hackers in December have …
BeiGene’s tislelizumab gets China approval for non-small cell lung cancer
January 14, 2021BeiGene, Cancer, tislelizumab
BeiGene Ltd has announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration (NMPA) …
ViiV gets EU approval for children’s HIV treatment
January 13, 2021Research and Development EU, HIV, ViiV
ViiV Healthcare, the global specialist HIV company, has received marketing authorisation from the European Commission for Tivicay (dolutegravir) 5mg dispersible …
Diurnal joins Er-Kim to distribute cortisol deficiency treatments in Turkey
January 13, 2021Research and Development Diurnal, Diurnal Group, Er-Kim, Turkey
Diurnal Group, a specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, has announced a distribution agreement with Er-Kim, …
Pfizer invests $25m in Vedanta BioSciences’ IBD treatment
January 13, 2021Research and Development Pfizer, Vedanta Biosciences, inflammatory bowel disease
Pfizer has invested $25 million in Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases, …
Trial of potential new COVID-19 treatment begins in UK
January 13, 2021Research and Development COVID-19, Synairgen, Vaccine
A large-scale trial of a new COVID-19 treatment to prevent severe illness in coronavirus patients has begun in the UK. …
Switzerland approves Moderna’s COVID-19 vaccine
January 13, 2021Research and Development COVID-19, Moderna, Vaccine
Moderna has announced that its COVID-19 vaccine has been authorised for use on those aged 18 or older in Switzerland. …
Novartis and BeiGene join forces to develop cancer drug tislelizumab
January 12, 2021Manufacturing and Production BeiGene, Cancer, Novartis
Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene Ltd in major markets outside of China, accelerating …
Sosei Heptares and PharmEnable collaborate on neurological drug research
January 12, 2021Manufacturing and Production PharmEnable, Sosei Heptares
Sosei Group Corporation and PharmEnable, a UK drug discovery company, have joined forces to apply their respective technologies to drive …
AstraZeneca seeks EU approval for COVID-19 vaccine
January 12, 2021Manufacturing and Production AstraZeneca, COVID-19, Vaccine
AstraZeneca has applied for conditional marketing authorisation (CMA) from the EMA for its COVID-19 vaccine. CMA is used as the …
Boehringer Ingelheim and Enara Bio to collaborate on cancer immunotherapies
January 12, 2021Manufacturing and Production Boehringer Ingelheim, Cancer, Enara Bio
Boehringer Ingelheim and Enara Bio have entered into a strategic collaboration and licensing agreement to research and develop novel targeted …
Promising new treatment for drug-resistant prostate cancer
January 12, 2021Manufacturing and Production Cancer
A new experimental drug could offer a promising treatment strategy for men with advanced, drug-resistant prostate cancer, researchers have said. …
Purespring Therapeutics to appoint Richard Francis as CEO
January 11, 2021Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Purespring Therapeutics, a kidney-focused AAV gene therapy company, has announced it will appoint Richard Francis as Chief Executive Officer from …
Eli Lilly’s Alzheimer’s drug slows clinical decline in Phase II trial
January 11, 2021Sales and Marketing Alzheimer's, Eli Lilly
Eli Lilly’s donanemab has shown significant slowing of decline in a composite measure of cognition and daily function in patients …
Roche’s influenza drug Xofluza gets EU approval
January 11, 2021Sales and Marketing EC, Roche, influenza
The European Commission (EC) has approved Roche’s Xofluza (baloxavir marboxil) for the treatment of uncomplicated influenza in patients aged 12 …
MaxCyte signs licensing deal with Myeloid Therapeutics
January 11, 2021Sales and Marketing MaxCyte, Myeloid Therapeutics
MaxCyte, a global cell-based therapies and life sciences company, and Myeloid Therapeutics, a company harnessing and reprogramming myeloid cells to …
Sanofi to acquire Kymab for $1.1bn
January 11, 2021Sales and Marketing Malin, Sanofi, kymab
Sanofi is to acquire clinical-stage biopharmaceutical company Kymab for approximately $1.1 billion. In addition to this upfront sum, Paris-headquartered Sanofi …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
